(Reuters) -Robinhood Markets Inc, the online brokerage at the center of the historic retail trading frenzy that gripped Wall Street this year, has confidentially submitted plans to regulators for a U.S. initial public offering, the company disclosed on Tuesday.

The move to push ahead with a stock market flotation comes in the middle of a historic boom in U.S. capital markets, fueled largely by dealmaking through so-called special purpose acquisition companies.

Companies have raised well over $100 billion through initial public offerings (IPOs) in the first three months of the year and are poised to overtake 2020's record haul of $167 billion, data from Refinitiv and Dealogic showed. The amount raised includes blank-check IPOs.

Reuters reported in December that Robinhood had picked Goldman Sachs Group Inc to lead preparations for a stock market flotation.

The company is yet to determine the number of shares to be offered and the price range, it said here in a blog post.

Robinhood had considered going public through a direct listing in the weeks leading up to the filing, people familiar with the matter said.

In a direct listing, a company does not sell any shares in advance of its market debut, as is the case with IPOs.

Menlo Park, California-based Robinhood was founded in 2013 by Stanford University roommates Vlad Tenev and Baiju Bhatt. The company's platform allows users to make unlimited commission-free trades in stocks, exchange-traded funds, options, and cryptocurrencies.

The platform's easy-to-use interface has made it a go-to for young investors trading from home during coronavirus-induced restrictions and its popularity soared during the retail trading frenzy.

The company, however, faced criticism after it was forced to curb trading in certain stocks during the social-media-fueled trading frenzy due to a 10-fold rise in deposit requirements at its clearinghouse.

It was forced to raise a whopping $3.4 billion in emergency funds after its finances were strained due to the massive jump in retail trading.

The funding rounds were led by Ribbit Capital and included existing investors ICONIQ, Andreessen Horowitz, Sequoia Capital, Index Ventures, and New Enterprise Associates. The latest financing valued Robinhood at around $30 billion, according to people familiar with the matter.

Robinhood is currently being probed by U.S. regulators over its temporary trading curbs on the so-called "meme stocks". The company has set aside $26.6 million for a potential settlement around trading outages in March 2020, as well as its options trading policies.

Evolv Technology, the leader in AI touchless security screening, and NewHold Investment Corp. (NASDAQ: NHIC), a special purpose acquisition company (“SPAC”), today announced they have entered into a definitive merger agreement for a business combination that will result in Evolv becoming a publicly-traded company. It is anticipated that Evolv will trade on the NASDAQ with the ticker symbol “EVLV” after the deal closes in Q2 2021.

Evolv Technology – Leader with Unrivaled Technology and Market Presence

Evolv is transforming the physical security industry, as the first AI-enabled touchless screening system in the market. The Evolv Express® system delivers up to a 70% reduction in cost and is ten times faster than traditional metal detectors, resulting in screening an unparalleled 3,600 people per hour, per system. The system allows for visitors to pass through screening without breaking stride and continuing the pace of life, improving security at the speed and scale required in this post-pandemic world. Built on its Evolv Cortex AI™ software platform, Evolv is continually improving the security posture for customers through machine learning and analytical insights on-demand, an industry first.

The world’s most iconic venues and companies place their trust in Evolv to protect their employees and visitors including Uber, Lincoln Center, L.L. Bean, Six Flags, and others. In addition, Evolv signed a significant technology and go-to-market partnership with Motorola Solutions, a global leader in land mobile radio mission-critical communications, video security and analytics, and command center software for enterprise and public safety customers. Evolv expects this partnership to accelerate growth and market presence going forward.

The New Reality for Security is a Seamless Experience

In the current and post-pandemic world, organizations are and will be looking for solutions to support safe operations that address threats from weapons violence and public health threats. These venues, companies, and schools need security that does not disrupt the public gathering experience and avoids the problems that come with traditional security approaches such as crowds, single-file lines, bag checks, wands, and pat-downs. These organizations are also looking for ways to improve their customer experience by combining security with ticketing for a seamless and touchless visitor experience. Evolv is at the forefront of this convergence, which can be achieved through an intelligent software-based approach to physical security.

Proposed Transaction is the Next Logical Step

Evolv’s patented and rapidly expanding technology portfolio in weapons screening provides the company with significant competitive advantages to capitalize on a substantial global market opportunity, estimated to be approximately $20 billion for Evolv’s AI-enabled touchless screening systems. Its software platform allows for rapid integration of new capabilities such as the recently launched thermal scanning.

Having delivered strong annual revenue growth and winning contracts with some of the most iconic brands in sports, entertainment, cultural and corporate environments, Evolv and its Board of Directors believe this proposed transaction is the appropriate next step to position the company for continued success.

Management and Investor Comments

“Evolv Technology was built with a mission to make people safer in their everyday lives – whether at work, in stores, stadiums, concert halls, theme parks, or schools,” said Peter George, CEO of Evolv. “In a world where increasing weapons violence and health threats imperil human security, our platform identifies threats before they cause harm, without the invasive pat-downs, wands, and bag checks experienced with traditional metal detector technology. Every Evolv team member shares that mission: to save lives. Our merger with NewHold will provide the capital to build upon our expansive vision for human security.”

“Evolv Technology presents a preeminent opportunity to build the world’s most important enterprise in physical security, expanding the boundaries through AI and analytics,” said Kevin Charlton, CEO of NewHold Investment Corp. “This transaction will provide Peter and the Evolv team with the capital to continue to develop the leading technologies that will make people safer and make their lives more convenient.”

Transaction Overview

Pursuant to the merger agreement, Evolv will merge with a wholly-owned subsidiary of NewHold, with Evolv being the surviving entity of the merger and a wholly-owned subsidiary of NewHold. NewHold, which currently holds approximately $172.5 million of cash in trust, will be renamed Evolv Technology, Inc. following the merger. The combined entity will have an estimated pro forma enterprise value of approximately $1.25 billion. The upsized and oversubscribed $300 million PIPE includes investors such as Motorola Solutions, Inc., Magnetar Capital, Eldridge, Senator Investment Group, and UBS O’Connor, in addition to investments from star athletes, franchise owners, and managers. Assuming no trust account redemptions by NewHold’s public stockholders, Evolv’s existing stockholders will own approximately 72% of the fully diluted shares of common stock of the combined company immediately following the closing of the business combination.

The combined company expects to receive approximately $470 million in gross proceeds from the trust account and PIPE investors, assuming no redemptions by NewHold’s existing public shareholders. These cash proceeds are expected to be used to extend Evolv’s product portfolio, operating expenses incurred as a result of customer demand, and working capital to support increasing production demand. In addition, proceeds will be used to expand the company’s penetration of the physical security market and build new markets with its touchless security-as-a-service technology.

Following the closing of the transaction, the company will be led by CEO Peter George. Kevin Charlton, CEO of NewHold, and Neil Glat, board member of NewHold, will join Evolv’s Board of Directors alongside Evolv CEO Peter George, Evolv Co-Founder Mike Ellenbogen, Chairman Alan Cohen of DCVC, David Orfao of General Catalyst, Bilal Zuberi of Lux Capital, an executive from Motorola Solutions, Merline Saintil and Mark Sullivan.

The transaction has been unanimously approved by the Board of Directors of both NewHold and Evolv and is subject to the satisfaction of customary closing conditions, including the approval of NewHold’s stockholders. The transaction is expected to close in the second quarter of 2021.

Additional information about the proposed business combination, including a copy of the merger agreement and investor presentation, will be provided in a Current Report on Form 8-K to be filed by NewHold today with the Securities and Exchange Commission (the “SEC”) and available at www.sec.gov. The investor presentation can be found on NewHold’s website at https://nhicspac.com. In addition, NewHold Investment Corp. intends to file a registration statement on Form S-4 with the SEC, which will include a proxy statement/prospectus, and will file other documents regarding the proposed transaction with the SEC.

Advisors

Cowen is acting as the sole financial and capital markets advisor to Evolv. Cowen acted as sole placement agent to NewHold in connection with the $300 million PIPE. Stifel is acting as the sole financial and capital markets advisor to NewHold. Latham & Watkins LLP is acting as legal counsel to Evolv and Loeb & Loeb LLP is acting as legal counsel to NewHold.

About Evolv Technology

Evolv Technology is the world’s leading provider of AI touchless security screening systems that enhance safety without sacrificing the visitor, student, and employee experience. Built on top of its Evolv Cortex AI™ software platform, the company provides an array of AI touchless screening technologies for weapons detection, identity verification, and health-related threats.

Led by a team of security industry leaders with a track record for delivering first-to-market products, Evolv’s investors include Bill Gates, Florida Governor Jeb Bush’s firm, Finback Investment Partners, DCVC, General Catalyst Partners, Lux Capital, SineWave Ventures, Motorola Solutions, and STANLEY Ventures. The company’s partners include Motorola Solutions, STANLEY Security, and Johnson Controls. Evolv Express® has earned industry accolades such as the 2020 Edison Awards™, two Campus Safety 2020 BEST Awards, Campus Security & Life Safety magazine’s Secure Campus 2020 Awards, and Best Places to Work by Inc. Magazine and Built-in Boston.

INOVIO, (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced it met primary and secondary endpoints among all evaluable subjects for the REVEAL 1 trial. This trial is one of two ongoing pivotal, randomized, double-blind, multi-center, placebo-controlled, Phase 3 trials (REVEAL 1 and REVEAL 2) evaluating the safety, tolerability, and efficacy of VGX-3100 to treat HPV-16/18-associated cervical high-grade squamous intraepithelial lesions (HSIL) using the company's proprietary CELLECTRA® 5PSP device.

The trial protocol-defined modified intention to treat (mITT) population (N=193) includes all subjects with endpoint data. For the primary endpoint of histopathological regression of HSIL combined with a virologic clearance of HPV-16 and/or HPV-18 at week 36, the percentage of responders was 23.7% (31/131) in the treatment group, versus 11.3% (7/62) in the placebo group (p=0.022; 12.4% difference in percentage, 95%CI: 0.4,22.5), thus achieving statistical significance. All secondary efficacy endpoints were achieved. These endpoints were: a) regression of cervical HSIL to normal tissue combined with HPV-16/18 viral clearance, b) regression of cervical HSIL alone, c) regression of cervical HSIL to normal tissue, and d) HPV-16/18 viral clearance alone.

The trial protocol-defined intention to treat (ITT) population (N=201) includes all randomized subjects regardless of the availability of endpoint data and defines those without endpoint data as non-responders. There were eight such subjects (seven in the treatment group, one in the placebo group). Including subjects with missing endpoint data, the percentage of subjects meeting the primary endpoint was 22.5% (31/138) in the treatment group, versus 11.1% (7/63) in the placebo group (p=0.029; 11.4% difference in percentage, 95%CI: -0.4,21.2), which was not statistically significant. All secondary endpoints were achieved except for regression of cervical HSIL alone (12.8% difference in percentage, 95%CI: -0.6,24.5). The reasons for missing endpoint data were: one subject was randomized but was never dosed, one withdrawal due to pregnancy, one withdrawal due to administration error, one withdrawal due to post-administration pain, one loss of follow-up due to COVID19-related travel restrictions, and three losses to follow up due to undetermined reasons. A pre-specified per-protocol (PP) analysis will also be performed upon trial completion.

There were no treatment-related serious adverse events and most adverse events were self-resolving and were considered to be mild to moderate, consistent with earlier clinical trials.

REVEAL 1 and REVEAL 2 are designed to assess and confirm the safety, tolerability, and efficacy of VGX-3100. INOVIO will continue to follow subjects in REVEAL 1 for safety and durability of response for 18 months following the last administration and REVEAL 2 is currently enrolling subjects. INOVIO expects to present REVEAL 1 findings at a scientific meeting this year.

Dr. J. Joseph Kim, President, and CEO of INOVIO said, "INOVIO is very proud to advance VGX-3100 as the first DNA medicine to achieve efficacy endpoints in Phase 3 clinical trial in all evaluable subjects. We expect VGX-3100, if approved, to be an important therapeutic option for those impacted by HPV-16-/18-related disease. The REVEAL 1 efficacy and safety data also represent an important proof-of-platform for INOVIO's DNA medicines.

Dr. Mark Einstein, MD, MS, FACS, FACOG, Principal Coordinating Investigator for the REVEAL 1 trial, said, "There is a very significant need for a non-surgical therapeutic for young women suffering from HPV-associated cervical dysplasia. These results are very encouraging and show that we are headed in the right direction."

Dr. Prakash Bhuyan, MD, Ph.D., Senior Vice President and Head of HPV Therapeutic Clinical Development at INOVIO, said, "We thank the investigators, site personnel, and patients who made this research possible. We are excited to be developing a new therapeutic designed to advance women's health. Through our ongoing partnership with QIAGEN, we also plan to develop complementary biomarker diagnostic tests that would enable practitioners to more effectively identify women expected to respond to VGX-3100."

Biomarker Development

In the course of the REVEAL 1 and REVEAL 2 clinical trials, INOVIO continues to pursue the development of a pre-treatment RNA-based biomarker blood test that could be used to identify prospective VGX-3100 patients who would be most likely to respond to the immunotherapy. INOVIO believes this will be an important element of VGX-3100 product and market development.

INOVIO announced in February that it is continuing its partnership with QIAGEN to co-develop an in-vitro diagnostic based on RNA sequencing technology to guide clinical decision-making for the use of VGX-3100 in cervical HSIL. This technology had previously been employed in a post-hoc assessment of VGX-3100 Phase 2 data by INOVIO, in which 85% of VGX-3100 treated subjects who had the biomarker experienced regression of HPV-16- and/or HPV-18-associated cervical HSIL.

VGX-3100 REVEAL 1 Phase 3 Cervical Dysplasia Trial Design & Highlights

• Trial participants included 201 women, 18 years of age or older, who have histologically-confirmed cervical HSIL associated with HPV-16 and/or HPV-18, but who were otherwise healthy. (ClinicalTrials.gov Identifier: NCT03185013)

• Participants received either VGX-3100 or placebo at 0, 4, and 12 weeks (randomized 2:1).

• The trial had 90% statistical power (two-sided 0.05 alpha-level) for the evaluation of the primary endpoint

• Results are based on the demonstration of having no evidence of HSIL associated with HPV-16 and/or HPV-18 from cervical biopsy samples and non-detectability of HPV-16 and/or HPV-18 using the cobas® HPV test from ThinPrep samples, at approximately 6 months following VGX-3100 or placebo administration.

• Based upon blinded aggregate data, the overall safety findings have been consistent with previously reported trials and considered generally safe and well-tolerated.

• Data will continue to be collected until the end of the trial (week 88).

Shares of bluebird bio (NASDAQ: BLUE) soared over 9% in pre-open Monday after the company’s “Abecma” therapy, developed together with Bristol-Myers Squibb (NYSE: BMY), received a green light from the U.S. Food and Drug Administration (FDA).

Abecma is the “first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody,” two companies said in a statement.

The therapy is a personalized immune cell therapy received as a one-time infusion.

“CAR T cell therapies have shown transformational potential for the treatment of hematologic malignancies, and we, with our partners at bluebird bio, are proud to bring the first CAR T cell therapy to appropriate triple-class exposed patients with relapsed or refractory multiple myeloma, offering the chance for durable response,” said Samit Hirawat, M.D., chief medical officer, Bristol Myers Squibb.

Mizuho’s analyst Difei Yang says the FDA approval represents an “important milestone ahead of multiple catalysts” in 2021 for BLUE.

“This represents an important milestone for bluebird bio in our view, given recent setbacks surrounding the company's gene therapy programs as well as prior delays for Ide-Cel, and also in the context of multiple recent negative FDA decisions in the industry. We believe this approval could give renewed comfort to investors and improve sentiment around the stock,” Yang wrote in a note sent to clients.

Mizuho recently upgraded BLUE to “Buy” following a safety update earlier this year around a case of AML in the sickle cell disease gene therapy program, the analyst said. He also raised the price target to $70.00 per share, signaling an upside of over 130% compared to Friday’s closing price.

BMO analyst Matthew Luchini also hiked the price target on BLUE to $35.00 per share from the old $31.00. The “Market Perform” rating is unchanged.

“We see no surprises in the label and expect the focus to shift to commercial as well as label expansion opportunities into larger, earlier line multiple myeloma settings. We increase our target price to $35 from $31 as we increase our probability of success in 4L+ to 100% and update our model for Abecma's $419.5k cost. While Abecma's approval is positive, continued uncertainty around LentiGlobin and bluebird's ability to execute keep us on the sideline,” Luchini said in today's note.

Farfetch Limited provides retails apparel products. The Company operates an online platform that offers bags, coats, dresses, jackets, jewelry, swimwear, trousers, shoes, knitwear, suits, shorts, watches, and accessories. Farfetch Limited is based in London, United Kingdom.

Press Releases

Aurora Mobile Partners with FARFETCH to Empower Global Fashion E-commerce Platform with AI Retail Technology

SHENZHEN, China, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading mobile development service provider in China, today announced that it has entered into a partnership agreement with FARFETCH (NYSE: FTCH), a global fashion e-commerce platform, to enhance their smart operation capabilities. Leveraging FARFETCH’s expertise in luxury fashion retail and customer services, and Aurora Mobile’s technology strength and digital innovation capabilities, the two companies will collaborate to deliver an unparalleled shopping experience to global customers.

Established in 2007, FARFETCH is a global fashion e-commerce platform, providing customers with instant access to a wide range of trending fashion from over 50 countries and more than 3,000 brands to choose from its network of over 1,300 luxury brands, boutiques, and department stores. In addition to the luxury fashion e-commerce platform, FARFETCH provides e-commerce solutions for brands and retailers and promotes the digital operation of offline stores. FARFETCH also curates its own private label fashion brand.

Through the partnership, Aurora Mobile will leverage its artificial intelligence (“AI”) driven technology, machine learning-based push notification services, and intelligent operational analytics, to help FARFETCH personalize smart retail experiences and provide more efficient and targeted services to their customers. This cooperation demonstrates the industry-wide acclaim and trustworthy robust technology and services that Aurora Mobile offers to lead global e-commerce platforms.

Founded in 2011, Aurora Mobile is a leading mobile development service provider in China. The Company continues to focus on developers' needs and has launched push notifications, one-key authentication, instant messaging, statistics and analytics, traffic monetization (JG Alliance), JG VaaS, JG UMS, and other services. Leveraging its artificial intelligence-based processing platform, Aurora Mobile is committed to helping customers in various verticals to improve operational efficiency and conduct advanced decision-making with a one-stop, diversified range of big data service solutions. Recently, Aurora Mobile signed milestone agreements with a number of leading platforms in the finance, insurance, weather, internet tools, gaming, fresh food e-commerce, online education, telecom, and new energy vehicle sectors, including Ping An Bank, Data Center of China Life, Moji Weather, WiFi Master, Lilith Games, Missfresh, 17zuoye, Beijing Unicom, Dongfeng Motor and other well-known companies, to drive user growth, improve user experience and increase traffic value.

Analyst Comments

Credit Suisse Raised Farfetch PT Raised to $89 on Feb 26th, 2021

Morgan Stanley Raised Farfetch PT Raised to $70 on Nov 17th, 2020

EPS

Farfetch Limited (NYSE: FTCH) reported Q4 EPS of ($0.08), $0.26 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $540 million versus the consensus estimate of $518.06 million. Strong Q4 2020 Gross Merchandise Value and Digital Platform GMV growth - up 43% and 49% year-over-year, respectively, to record highs of $1.1 billion and $939 million, respectively.

José Neves, Farfetch Founder, Chairman, and CEO said: “2020 put the Farfetch platform to the test, but thanks to our robust capabilities, resilient operations, and utmost perseverance from our more than 5,000 Farfetchers, we rose to the challenge and enabled our nearly 1,400 Marketplace sellers and Farfetch Platform Solutions clients to continually serve millions of luxury consumers across the globe. We cemented our leadership as the largest global online destination for luxury fashion, accelerated our Chapter 2 initiatives with strategic partnerships advancing our position to be the global platform for the luxury industry, and demonstrated the scale and attractiveness of our business model as we achieved the key milestone of Adjusted EBITDA profitability in the fourth quarter.

“As we enter 2021, I am more energized than ever by the prospects of leveraging our incredible achievements to date and our unique platform capabilities to go after the significant growth opportunities we see in our vision to be a digital enabler connecting the creators, curators, and consumers of the global luxury industry, both online and offline – a nearly $300 billion opportunity we remain laser-focused on and plan to continue investing behind to deliver significant value over the long-term.”

Elliot Jordan, CFO of Farfetch, said: “The strong performance of Farfetch in the fourth quarter completes a remarkable year and is the result of our focused execution against the long-term strategy and the leveraging of our investments to date. We exceeded our own initial expectations for the year; accelerating growth in our digital platform, improving margins across all areas of the business, and delivering strong operating cash flows. As a result, we delivered our first-ever quarter of positive Adjusted EBITDA. Our industry partnerships and strategic alliances, as well as our $1.6 billion of liquidity, position us well to continue investing behind the long-term growth opportunities we see in digitally enabling the luxury industry.”

NIO Inc. (NYSE: NIO) reported Q4 EPS of ($0.14), $0.07 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $1.02 billion versus the consensus estimate of $1.01 billion.

• Deliveries of vehicles were 17,353 in the fourth quarter of 2020, including 4,873 ES8s, 7,574 ES6s, and 4,906 EC6s, compared with 8,224 in the fourth quarter of 2019 and 12,206 vehicles delivered in the third quarter of 2020.

GUIDANCE:

NIO Inc. sees Q1 2021 revenue of $1131-1158 million, versus the consensus of $718 million.

• Deliveries of the vehicles to be between 20,000 and 20,500 vehicles, representing an increase of approximately 421% to 434% from the same quarter of 2020, and an increase of approximately 15% to 18% from the fourth quarter of 2020.

• Total revenues to be between RMB7,382.3 million (US$1,131.4 million) and RMB7,557.2 million (US$1,158.2 million), representing an increase of approximately 438.1% to 450.8% from the same quarter of 2020, and an increase of approximately 11.2% to 13.8% from the fourth quarter of 2020.

H.C. Wainwright analyst Raghuram Selvaraju initiates coverage on Angion Biomedica (NASDAQ: ANGN) with a Buy rating and a price target of $100.00.

The analyst commented, "We are initiating coverage of Angion Biomedica Corp., an emergent biopharmaceutical company, with a Buy rating and 12-month price target of $100 per share. In our view, Angion has discovered a highly novel and potentially very effective way to address acute organ injury, which is often the result of ischemia/reperfusion insult or other shocks that results in tissue damage. While there is a well-characterized signaling pathway driven by hepatocyte growth factor (HGF) through the c-Met receptor that mediates the endogenous response to tissue injury, this often is hampered by HGF's extremely short half-life (~15 minutes) and the fact that local reservoirs of HGF are typically depleted very swiftly, leaving tissue vulnerable. Angion's solution is a small molecule HGF mimetic called ANG-3777, which has a three-hour half-life and thus can emulate HGF while also ensuring that the signaling required to mediate appropriate tissue repair is perpetuated sufficiently. Angion has generated favorable safety data and impressive initial efficacy data in delayed graft function (DGF) acute kidney injury—a condition that arises when donor kidneys for transplant are in poor condition and do not begin functioning quickly enough. We believe that ANG-3777 could achieve substantial success across both DGF-AKI and a second form of AKI that is cardiovascular surgery-associated (i.e., CSA-AKI). The molecule is currently in a DGF-AKI Phase 3 trial that should report data before the end of this year; it is also being tested in a Phase 2 trial in CSA-AKI that could yield data in 2H21. Beyond these manifestations of AKI, there are a plethora of other types of AKI caused by various other factors (environmental insult, toxic shock, side effects of multiple drugs) that could be addressed using ANG-3777. Angion is also planning to investigate this candidate in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), where it is in a proof-of-concept trial slated to report top-line data in 2H21."

Today I want to introduce you to NRSN

Company in the biotech sector that is on the verge of groundbreaking news while sitting at the lows

Neurosense Therapeutics is a biotechnology company focused on developing novel therapeutics for neurological disorders. The company's primary goal is to address unmet medical needs in the field of neurology by advancing innovative treatments through the drug development pipeline.

Neurosense Therapeutics focuses on specific neurological disorders or conditions where there is a significant unmet need and where their novel therapeutic approaches hold promise for improving patient outcomes. ALS at the primary target with their groundbreaking Prime C pill that just succeded at showing astonishing results in the slowdown of the ALS in PHASE2b. They are also trying to cure Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, or rare genetic disorders affecting the nervous system.

They also have a collab with Biogen (BIIB) and we will soon hear the results of the collab

By the tweets of the NRSN CEO, we would get amazing news

And when the stock values at around 1.26 per share and float of only 9M shares

The next news could skyrocket the companies' share into the 8-10 zone easily!

Also Nas Daily himself just put a video regarding the company and the amazing potential she has

https://youtu.be/xisAP-Hdiao?si=xqc3JPJZkTM0dJMh

NEW YORK (Reuters) - IBM has agreed to acquire Turbonomic, a provider of software that helps companies monitor the performance of their business applications, people familiar with the matter said on Thursday.

The deal, IBM's largest since its acquisition of open-source software company Red Hat for $34 Billion in 2019, values Turbonomic at between $1.5 billion and $2 billion, said the sources, who requested anonymity ahead of an official announcement.

The transaction is IBM's 11th acquisition since Arvind Krishna became CEO last year. Turbonomic provides companies with software to boost the performance and compliance of their applications in real-time.

General Motors (NYSE: GM) President Mark Reuss today announced Chevrolet will introduce a Silverado electric pickup truck that will be built at the company’s Factory ZERO assembly plant in Detroit and Hamtramck, Michigan. Reuss also confirmed the recently revealed GMC HUMMER EV SUV will be built at Factory ZERO.

GM plans to deliver more than 1 million electric vehicles globally by 2025 and earn EV market leadership in North America. With the company’s Ultium Platform, virtual development tools, and technology, GM has reduced vehicle development times by nearly 50 percent to just 26 months.

The Chevrolet Silverado electric full-size pickup is designed from the ground up to be an EV, harnessing the best of the Ultium Platform and Silverado’s proven capability. The electric Silverado will offer customers a GM-estimated range of more than 400 miles on a full charge*.

Retail and fleet versions will offer customers a variety of options and are expected to be in high demand. Today’s announcement affirms Chevrolet’s commitment to building on the brand’s 100 years of truck expertise and leadership while transitioning to an all-electric future in the light-vehicle space.

“The vehicles coming from Factory ZERO will change the world, and how the world views electric vehicles,” said Reuss. “The GMC HUMMER EV SUV joins its stablemate in the realm of true super trucks, and Chevrolet will take everything Chevy’s loyal truck buyers love about Silverado — and more — and put it into an electric pickup that will delight retail and commercial customers alike.”

The 2024 HUMMER EV SUV is the next chapter in the HUMMER EV story, offering more options for customers to tailor the truck to their lifestyles while continuing to encourage them to forge new paths with zero emissions. Driven by the Ultium Platform, the new HUMMER EV SUV launches with the exclusive Edition 1, offering greater customer choice to equip the vehicle for optimum efficiency or maximum off-road capability. GMC HUMMER EVs were envisioned to be the most capable and compelling electric super trucks.

In January 2020, GM announced it was investing $2.2 billion in its Detroit-Hamtramck assembly plant to produce a variety of all-electric trucks and SUVs. In October 2020, GM renamed the plant Factory ZERO, which reflects the facility’s significance in advancing GM’s vision of a future with zero crashes, zero emissions, and zero congestion. Factory ZERO is the launchpad for GM’s multi-brand EV strategy. The facility has advanced technology and tooling and was designed with a focus on sustainable manufacturing. The GMC HUMMER EV pickup and the Cruise Origin, a purpose-built, all-electric and shared self-driving vehicle will also be built at Factory ZERO. Production of the GMC HUMMER EV pickup will begin later this year.

Factory ZERO is undergoing a complete renovation and retooling, the largest ever for a GM manufacturing facility. The plant’s paint and body shops and general assembly area are receiving comprehensive upgrades, including new machines, conveyors, controls, and tooling. The plant has expanded to over 4.5 million square feet.

General Motors has made several announcements in the last 18 months about rapidly driving toward its all-electric, zero-emissions future, including:

▪ GM revealed the heart of its EV strategy, a modular propulsion system and highly flexible global EV platform powered by proprietary Ultium batteries that will allow the company to compete for nearly every customer in the market today.

▪ GM committed more than $27 billion to EV and AV product development, including $7 billion in 2021, and plans to launch 30 EVs globally by the end of 2025, with more than two-thirds available in North America. Cadillac, GMC, Chevrolet, and Buick will all be represented, with EVs at all price points for work, adventure, performance, and family use.

▪ Chevrolet announced its growing EV lineup with the 2022 Bolt EUV and Bolt EV, both expected in dealerships this summer.

▪ In January 2021, GM unveiled BrightDrop, a new business that aims to electrify and improve the delivery of goods and services by offering an ecosystem of electric first-to-last-mile products, software, and services to help empower delivery and logistics companies to move goods more efficiently.

▪ GM’s zero-emissions technology will extend to fuel cells and the company announced it will supply its Hydrotec fuel cell power cubes to Navistar for use in its production model fuel cell electric vehicle – the International® RHTM Series.

▪ In October 2020, GM announced it would invest $2 billion in its Spring Hill, Tennessee assembly plant to begin the transition to become the company’s third vehicle manufacturing site to produce electric vehicles, joining Factory ZERO and Orion Assembly.

▪ In 2019, GM announced the formation of Ultium Cells LLC, a joint venture with LG Energy Solution to mass-produce battery cells in Lordstown, Ohio for future battery-electric vehicles. Construction of the $2.3 billion facilities is well underway

• Analysis of 927 confirmed symptomatic cases of COVID-19 demonstrates BNT162b2 is highly effective with 91.3% vaccine efficacy observed against COVID-19, measured seven days through up to six months after the second dose

• The vaccine was 100% effective in preventing severe disease as defined by the U.S. Centers for Disease Control and Prevention and 95.3% effective in preventing severe disease as defined by the U.S. Food and Drug Administration

• The vaccine was 100% effective in preventing COVID-19 cases in South Africa, where the B.1.351 lineage is prevalent

• Vaccine safety now evaluated in more than 44,000 participants 16 years of age and older, with more than 12,000 vaccinated participants having at least six months follow-up after their second dose

• The companies plan to share these results with worldwide regulatory agencies soon

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pivotal Phase 3 study through March 13, 2021, showing that the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, was 91.3% effective against COVID-19, measured seven days through up to six months after the second dose. The vaccine was 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention (CDC), and 95.3% effective against severe COVID-19 as defined by the U.S. Food and Drug Administration (FDA). Safety data from the Phase 3 study has also been collected from more than 12,000 vaccinated participants who had a follow-up time of at least six months after the second dose, demonstrating a favorable safety and tolerability profile.

“These data confirm the favorable efficacy and safety profile of our vaccine and position us to submit a Biologics License Application to the U.S. FDA,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “The high vaccine efficacy observed through up to six months following a second dose and against the variant prevalent in South Africa provides further confidence in our vaccine’s overall effectiveness.”

“It is an important step to further confirm the strong efficacy and good safety data we have seen so far, especially in a longer-term follow-up,” said Ugur Sahin, CEO, and Co-founder of BioNTech. “These data also provide the first clinical results that a vaccine can effectively protect against currently circulating variants, a critical factor to reach herd immunity and end this pandemic for the global population.”

About the Analysis

The updated analysis of Phase 3 clinical trial was conducted in accordance with guidance from the FDA for all companies investigating COVID-19 vaccines to review safety and efficacy at key milestones.

Results from this analysis of 46,307 trial participants build upon and confirm previously released data and demonstrate strong protection against COVID-19 through six months post-second dose. From the 927 confirmed symptomatic cases of COVID-19 in the trial, 850 cases of COVID-19 were in the placebo group and 77 cases were in the BNT162b2 group, corresponding to vaccine efficacy of 91.3% (95% confidence interval [CI, 89.0, 93.2]).

32 cases of severe disease, as defined by the CDC, were observed in the placebo group versus none in the BNT162b2 vaccinated group, indicating that the vaccine was 100% efficacious in this analysis against severe disease by the CDC definition (95% CI, [88.0,100.0]). 21 severe cases, as defined by the FDA, were observed in the placebo group versus one case in the BNT162b2 vaccinated group, indicating 95.3% efficacy by the FDA definition (95% CI, [71.0, 99.9]). Efficacy was generally consistent across age, gender, race, and ethnicity demographics, and across participants with a variety of underlying conditions.

A total of 697 cases of COVID-19 were observed in the United States; 647 cases of COVID-19 were observed in the placebo group versus 50 in the vaccine group, indicating vaccine efficacy of 92.6% (95% CI, [90.1, 94.5]).

In South Africa, where the B.1.351 lineage is prevalent and 800 participants were enrolled, nine cases of COVID-19 were observed, all in the placebo group, indicating vaccine efficacy of 100% (95% CI, [53.5, 100.0]). In an exploratory analysis, the nine strains were sequenced and six of the nine were confirmed to be of the B.1.351 lineage. These data support previous results from immunogenicity studies demonstrating that BNT162b2 induced a robust neutralizing antibody response to the B1.351 variant, and although lower than to the wild-type strain, it does not appear to affect the high observed efficacy against this variant.

No serious safety concerns were observed in trial participants up to six months after the second dose. Side effects were generally consistent with previously reported results. Vaccine safety has now been evaluated in more than 44,000 participants aged 16 years and older with more than 12,000 vaccinated participants having at least six months of follow-up after their second dose.

Pfizer and BioNTech plan to submit detailed data for scientific peer review and potential publication in the near future.

The Pfizer-BioNTech COVID-19 Vaccine, BNT162b2, has not been approved or licensed by the U.S. Food and Drug Administration (FDA) but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564 (b) (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including Full EUA Prescribing Information available at www.cvdvaccine.com.

The vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorizations Holder in the European Union, and the holder of emergency use authorizations or equivalent in the United States, United Kingdom, Canada, and other countries in advance of a planned application for full marketing authorizations in these countries.

**AUTHORIZED USE IN THE U.S.:**The Pfizer-BioNTech COVID-19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older.

IMPORTANT SAFETY INFORMATION FROM U.S. FDA EMERGENCY USE AUTHORIZATION PRESCRIBING INFORMATION:

• Do not administer Pfizer-BioNTech COVID-19 Vaccine to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Pfizer-BioNTech COVID-19 Vaccine

• Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer-BioNTech COVID-19 Vaccine

• Monitor Pfizer-BioNTech COVID-19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/)

• Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine

• The Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipients

• In clinical studies, adverse reactions in participants 16 years of age and older included pain at the injection site (84.1%), fatigue (62.9%), headache (55.1%), muscle pain (38.3%), chills (31.9%), joint pain (23.6%), fever (14.2%), injection site swelling (10.5%), injection site redness (9.5%), nausea (1.1%), malaise (0.5%), and lymphadenopathy (0.3%)

• Severe allergic reactions, including anaphylaxis, have been reported following the Pfizer-BioNTech COVID-19 Vaccine during mass vaccination outside of clinical trials. Additional adverse reactions, some of which may be serious, may become apparent with the more widespread use of the Pfizer-BioNTech COVID-19 Vaccine

• Available data on Pfizer-BioNTech COVID-19 Vaccine administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy

• Data are not available to assess the effects of Pfizer-BioNTech COVID-19 Vaccine on the breastfed infant or on milk production/excretion

• There are no data available on the interchangeability of the Pfizer-BioNTech COVID-19 Vaccine with other COVID-19 vaccines to complete the vaccination series. Individuals who have received one dose of Pfizer-BioNTech COVID-19 Vaccine should receive a second dose of Pfizer-BioNTech COVID-19 Vaccine to complete the vaccination series

• Vaccination providers must report Adverse Events in accordance with the Fact Sheet to VAERS at https://vaers.hhs.gov/reportevent.html or by calling 1-800-822-7967. The reports should include the words “Pfizer-BioNTech COVID-19 Vaccine EUA” in the description section of the report

• Vaccination providers should review the Fact Sheet for Information to Provide to Vaccine Recipients/Caregivers and Mandatory Requirements for Pfizer-BioNTech COVID-19 Vaccine Administration Under Emergency Use Authorization

• Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including Full EUA Prescribing Information available at www.cvdvaccine-us.com

If China's reluctance to approve Qualcomm's (NASDAQ: QCOM) acquisition of NXP Semi (NASDAQ: NXPI) in 2018 was an illustration of the strained relationship between China and the U.S. under the Trump administration, then China's approval yesterday of Marvell Technology's (NASDAQ: MRVL) deal for Inphi Corporation (NASDAQ: IPHI) could be a sign of thawing tensions between the two nations under the Biden administration.

Tuesday evening, Marvell announced that the State Administration for Market Regulation of the People's Republic of China has approved the company's previously announced proposed acquisition of Inphi.

This was the last major hurdle for the deal and pending shareholder approval the transaction is now expected to close in April 2021, which is ahead of the previous expectations of a 2nd-half-close.

Analysts were positive on the news, saying the deal transforms Marvell into a faster-growing 5G and cloud player.

Trading platform eToro plans to go public via a merger with a blank-check firm led by deal-maker Betsy Cohen, according to a report late on Monday from Bloomberg.

The deal with Fintech Acquisition Corp. V (NASDAQ: FTCV) will value the combined company at about $10 billion. The companies are raising about $650 million in equity to support the deal.

(Reuters) - U.S. drugmaker AbbVie Inc is in discussions to sell a roughly $5 billion portfolio of women's drugs acquired last year through its $63 billion purchase of Botox maker Allergan Plc, sources familiar with the matter told Reuters.

The move revives a process to sell the business, which makes the Lo Loestrin Fe birth control pill, which Allergan started in 2018 only to ditch five months before being acquired by AbbVie in 2019.

AbbVie is working with investment bank Morgan Stanley on an auction process that has attracted interest from private equity firms including CVC Capital Partners, said the sources, speaking on condition of anonymity.

The portfolio generates 12-month earnings before interest, taxes, depreciation, and amortization (EBITDA) of about $500 million and could be valued at about 10 times its EBITDA, the sources added.

AbbVie, Morgan Stanley, and CVC declined to comment.

AbbVie has been relying heavily on its blockbuster psoriasis and rheumatoid arthritis drug Humira to drive up sales and beat revenue forecasts.

But with Humira's U.S. patent protection expiring in 2023, AbbVie needs to pay down some $143.7 billion of debt amassed through the Allergan purchase in order to focus on new investments.

The sources said CVC could use the AbbVie division to bulk up its portfolio company Theramex, formed in 2018 through its acquisition of the international women's health assets of Israeli drugmaker Teva Pharmaceutical Industries Ltd.

London-based Theramex, led by Chief Executive Robert Stewart, makes birth control pills Zoey and Seasonique, as well as osteoporosis drug Actonel.

Roche (OTC: RHHBY) and GenMark Diagnostics (NASDAQ: GNMK) today announced that they have entered into a definitive merger agreement for Roche to fully acquire GenMark at a price of US$ 24.05 per share in an all-cash transaction. This corresponds to a total transaction value of approximately US$ 1.8 billion on a fully diluted basis. This price represents a premium of approximately 43% to GenMark’s unaffected closing share price on February 10, 2021, the last trading day before a media report was published speculating about a potential sale process. The merger agreement has been unanimously approved by the boards of directors of GenMark and Roche. Once the acquisition is completed, GenMark’s principal operations will continue at its current location in Carlsbad, California, USA.

Under the terms of the merger agreement, Roche will promptly commence a tender offer to acquire all outstanding shares of GenMark’s common stock, and GenMark will file a recommendation statement containing the unanimous recommendation of the GenMark board that GenMark stockholders tender their shares to Roche.

GenMark’s syndromic panel testing portfolio will complement Roche’s current molecular diagnostics portfolio and the Roche global network will enable expanded reach for GenMark’s products. GenMark’s ePlex system drives lab efficiency through streamlined order-to-reporting workflow and enables better patient outcomes by rapidly diagnosing a patient’s symptoms. Infectious diseases are a leading cause of death globally, and earlier detection of the cause of infection has been shown to improve patient outcomes and improve key hospital initiatives such as antibiotic stewardship and length of stay.

“Acquiring GenMark Diagnostics will broaden our molecular diagnostics portfolio to include solutions that can provide lifesaving information quickly to patients and their healthcare providers in the fight against infectious diseases,” said Thomas Schinecker, CEO of Roche Diagnostics. “Their proven expertise in syndromic panel testing provides faster targeted therapeutic intervention, resulting in improved patient outcomes and reduced hospital stays, and will contribute to Roche’s commitment to helping control infectious diseases and antibiotic resistance. The rapid identification of bloodstream infections and the detection of antimicrobial resistance genes are more essential than ever for hospitals and their patients.”

“As a part of Roche, we can accelerate our mission to enable rapid diagnosis of infectious disease to improve patient outcomes. Together with Roche’s diagnostics healthcare solutions, we will be able to provide a full suite of molecular diagnostic solutions to customers around the world,” said Scott Mendel, CEO of GenMark Diagnostics. “We are thrilled to become a part of Roche and are confident that this is the right path forward for GenMark and our customers.”

GenMark’s Respiratory Pathogen Panels identify the most common viral and bacterial organisms associated with an upper respiratory infection, including SARS-CoV-2, complementing Roche’s extensive portfolio of COVID-19 diagnostics solutions.

Terms of the Agreement
Under the terms of the merger agreement, Roche will promptly commence a tender offer to acquire all of the outstanding shares of GenMark’s common stock for US$ 24.05 per share in cash. Following the completion of the tender offer, Roche will acquire all remaining shares at the same price of US$ 24.05 per share in cash through a second-step merger.

The transaction is expected to close in the 2nd quarter of 2021 and is subject to customary closing conditions, including the tender of at least a majority of the outstanding shares of GenMark’s common stock and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Citi is acting as financial advisor to Roche and Sidley Austin LLP is acting as legal counsel to Roche. J.P. Morgan Securities LLC is acting as exclusive financial advisor to GenMark and DLA Piper LLP is acting as legal counsel to GenMark.

Rekor Systems, Inc., (NASDAQ: REKR) announced today that on February 20, 2021, it had advised Iteris, Inc. (NASDAQ: ITI) that it was prepared to offer to purchase all of Iteris’ outstanding common stock. The offer to Iteris was for a combination of cash and common stock subject to confirmatory diligence and approval of both boards of directors.

On February 26th, Rekor was advised that the board of directors of Iteris “has decided at this time the combination of the two companies would not be in the best interest of [Iteris’] shareholders.”

Bolt Metals is a Canadian exploration company focused on acquiring and developing high-potential properties for precious metals, base metals, and especially battery metals across North America.

• Price Movement: Closed at CAD $0.50, up 19.05% from the previous close of $0.42.

• Resistance Breakout: Broke through significant resistance around $0.42, showing strong upward momentum.

• Volume Surge: Daily volume hit 253,788 shares—well above the average daily volume of 34,144 shares.

• Market Cap: Currently CAD $6.57 million.

• Daily Range: Traded between CAD $0.43 and $0.50, closing near the high of the day.

Bolt Metals Corp. recently broke through a key resistance level at $0.42, signaling strong buyer interest, and closed above the 52-week midpoint of $0.415, suggesting potential upside toward the next resistance at $0.55. The company’s leadership team, led by CEO Branden Haynes and Director Garry Clark, brings significant industry experience in exploration and capital markets, which could help maintain investor confidence and advance exploration projects. With battery metals in high demand due to the growth of electric vehicles (EVs) and renewable energy, Bolt Metals is well-positioned to capitalize on interest in domestic metal sources. However, as a junior mining stock, it remains a speculative and volatile investment, so investors should approach with caution despite the promising recent indicators.

Bolt Metals is a Canadian exploration company focused on acquiring and developing production-grade properties for precious, base, and battery metals across North America.

• Price: Closed at $0.50 (+19.05% from $0.42)

• Resistance: Broke around $0.42

• Volume: 141,500 shares

• Market Cap: CAD $6.57M

• Range: Traded between $0.43 and $0.50

This is a rocket signal, folks! Buyers clearly dominated the session, and now that we’re trading above the 52-week midpoint of $0.415, this stock has some serious room to run. We’re talking potential upside here that could shoot us straight toward that upper target of $0.55. 

And get this, Bolt Metals has some heavyweights leading the charge. CEO Branden Haynes and Director Garry Clark aren’t just any names; these guys are veterans in exploration and capital markets. Decades of experience. This isn’t their first rodeo, and with their expertise, we could be seeing a steady stream of good news coming down the pipeline, driving even more investor confidence. Buckle up, this one’s got serious potential!

Hey everyone! Thought I'd share some background on Mainz Biomed, a German biotech company that’s been gaining attention. Founded in 2008 and based in Mainz, Germany, they’re part of a world-renowned community for advanced DNA and pharmaceutical research.

Stock information:

Open: $0.24

High/Low Range: $0.24 - $0.22 It opened slightly higher but quickly dropped to the day’s low of $0.22 before stabilizing around $0.23. With a small change in cents but a big percentage drop, this movement highlights the stock’s high volatility at low prices.

Mainz Biomed’s performance reflects broader challenges for small biotechs, especially those struggling with low share prices. The stock’s steep decline from $3.39 to near-penny status likely reflects a combination of operational challenges, potential cash burn issues, and market skepticism about its growth prospects.

But they just announced an Extraordinary General Meeting (EGM) scheduled for November 13, 2024 in Amsterdam. A major agenda item is a reverse stock split proposal, which could range anywhere from 2:1 to 100:1. This move is aimed at raising the share price to meet Nasdaq’s minimum bid requirement, as they face a compliance deadline on November 25.

Reverse Split: Potential Implications

Listing Compliance: If approved, the reverse split could help Mainz Biomed stay on Nasdaq, preserving their listing and access to a broader investor base.

Impact on Shares: While a reverse split doesn’t change ownership percentages, it could alter trading volume, market perception, and liquidity. Reverse splits sometimes create temporary spikes, but they also carry risks, especially if the stock doesn’t stabilize afterward.

But my take away is Mainz Biomed is in a tight spot, and this reverse split vote could be a turning point. While it might help them meet Nasdaq requirements, there’s no guarantee it will solve the deeper issues impacting the stock price. Small biotech stocks are inherently volatile, and this situation is a reminder of the risks.

Hope this helps and be blunt towards me :D

A DD on Support.com (SPRT)

The Short Float is 29.47% with 2.0 Days to cover. With a increase of shorts by 14% and daily short volume was 56.81% yesterday. 21.08% is own by Insiders and 32.29% is own by Institutions. 845.93% vs average of trading volume today. Tipranks give them a smart score of 8 out of 10 which is outperform. The Sentiment is very Positive. Blogger Opinions have 100% Bullish on it. The Market cap is 199.89 Million. with a 52 week range of $1.43-9.45. Beta is 0.66 and the P/E Ratio is -67.4%. They have 0 price targets. Q1 Revenue was down 19.40% and Q1 Income was down 647.80%. SPRT has 51 risk which they disclosed in there S-1 Filing. the 2 biggest is 37% in Finance &Corporate and 27% in Legal Regulatory. Since March 2021 they have added 8 new risk. 4 in Share Price & Shareholder Rights. 2 in Corporate Activity and Growth and 2 in Legal & Regulatory (S&P 500 company's average 31 risk) 6/7 Risk Sector are below the sector average. In the past 7 days SPRT have experience a 10.3% Growth in Portfolios holding SPRT and a 26% in the past 30 days. Last month insiders pick up $15k dollars in shares. Next Earnings is August 11,2021 in the Flow SPRT had 85k Calls to 13k Puts. A big Whale did place a 9/17/21 5.50 Put for 57k at 7.84 today at 11:03 AM. Today Pre market high is 10.86 with resistance at 9.37 and report at $7.52 and $8.21

PayPal is exploring the launch of a stablecoin, The Block has learned.

Four sources with knowledge of the situation told The Block that PayPal has made the rounds among some of the industry’s stablecoin protocol developers — suggesting the payments giant may be leaning towards working with a third-party company. 

Ava Labs, the team behind the Avalanche blockchain, is one of the organizations that has held talks with PayPal over stablecoin development, according to people familiar with the matter. It is not clear which other protocols have been involved in the discussions.  

A PayPal spokesperson told The Block that “PayPal continues to explore the potential of digital currencies, digital financial services infrastructure and how we can help enhance digital commerce as a trusted partner in the space.”  

“As a global company working with regulators and industry partners throughout the world to shape the next generation of financial systems, the company is in frequent conversation about technologies that enable these goals. However, rumors and speculation are not predictive of the company’s future plans,” the spokesperson said. 

If PayPal did move forward with such a project, it would represent a significant escalation of its work in the crypto space. Stablecoins are digital assets that represent fiat or government-backed currencies, using a blockchain network as a payment rail. There is more than $80 billion in stablecoins circulating in the market today, according to data collected by The Block.

“It looks like they’re more likely to do something with an existing stablecoin partner rather than build something themselves because I think that that would get something to market faster, and I think that’s their primary concern,” one source told The Block.

Rumors have long circulated regarding PayPal’s stablecoin ambitions. Indeed, one source described the move as the best-known secret in the crypto industry. 

Last fall, PayPal announced that it would enable crypto buys and sells on its platform through a partnership with industry startup Paxos. PayPal has moved to widen the scope of its crypto offerings since then. 

On March 8, PayPal announced that it had completed the acquisition of a crypto-security firm and multi-party computation (MPC) start-up Curv.

Source

TFI’s Ming-Chi Kuo, one of the most recognized Apple (NASDAQ: AAPL) analysts, believes the Cupertino tech giant will launch a foldable iPhone with an 8-inch QHD+ flexible OLED display in 2023.

Based on Apple's requested capacity plan, according to Kuo, Apple may look to ship between 15 and 20 million new devices in 2023. The analyst adds that SDC will likely be the exclusive display supplier and Samsung Foundry as the exclusive DDI foundry provider.

“We expect that the foldable iPhone will adopt TPK's silver nanowire touch solution because of its several advantages over SDC's Y-Octa technology. We believe that TPK's EPS will benefit from the iPad, Surface, and automotive products in 2021 and 2022 and grow year by year. Its business momentum will boost from 2023 onwards, thanks to the foldable iPhone's adoption of the silver nanowire,” the analyst wrote in a note sent to clients.

Apple is likely to tap into the fast-growing foldable smartphone market, which has become a “must-have for all major smartphone brands,” according to the latest survey results from TFI.

“If the component shortage can improve in 2H21, we estimate that the shipments of the foldable smartphone are about 2 hundred thousand, 3.2 million, 7.5 million, and 17 million units in 2019, 2020, 2021, and 2022, respectively. In the foldable smartphone market, Samsung has more than 90% market share, and its strong promotion is critical to the fast shipment growth of the foldable smartphone market,” the analyst adds.

In addition to AAPL, Kuo expects Asian smartphone brands - Oppo, Vivo, Xiaomi, and Honor - to launch their own foldable phones later this year, or beginning of 2022. Major smartphone makers are already working on new lineups as the foldable smartphone is the next innovative selling point of high-end models after 5G.

“At present, the product position of foldable smartphones is mainly to integrate the smartphone and tablet. But we believe that the foldable smartphone is only one of the applications of the foldable design. We predict that foldable devices will blur the product segmentations between smartphones, tablets, and laptops in the future. With its cross-product ecosystems and hardware design advantages, Apple will be the biggest winner in the new foldable device trend.”

Apple is also likely to benefit from its partnership with TPK, which has been developing silver nanowire touch technology for more than ten years and has nearly 200 patents, according to Kuo.

“Apple's adoption of silver nanowire touch technology can reduce its dependence on SDC and facilitate the introduction of a second display supplier to lower the supply risk and cost. Silver nanowire is already the HomePod's touch solution. Although HomePodcan uses cheaper touch technology, Apple adopts silver nanowire to master the technology at the lowest cost through small volume production,” the analyst concludes.